Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Donald Parker

Internal Medicine Tupelo, MS Medical Doctor

NPI 1801835343 CMS profile 217460

1265 Cliff Gookin Blvd, Tupelo, MS 38801

Open in the dashboard

General payments

$5,391

372 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Donald Parker of Tupelo, MS is reported in the CMS Open Payments database as having received $5,391 across 372 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $121 5
2024 General $20 1
2023 General $50 3
2022 General $1,525 96
2021 General $1,452 102
2020 General $1,050 69
2019 General $1,172 96

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Donald Parker
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Donald Parker were reported at $121. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Donald Parker Internal Medicine median Middle half National median
2019 $1,172 $159 $48–$570 $163
2020 $1,050 $119 $33–$402 $114
2021 $1,452 $135 $37–$521 $132
2022 $1,525 $141 $42–$496 $149
2023 $50 $149 $45–$519 $160
2024 $20 $154 $47–$537 $164
2025 $121 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $584 44 payments
  2. Amgen Inc. $477 35 payments
  3. Lilly USA, LLC $464 37 payments
  4. AstraZeneca Pharmaceuticals LP $453 23 payments
  5. AbbVie, Inc. $347 26 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $329 23 payments
  7. Pfizer Inc. $286 23 payments
  8. Astellas Pharma US Inc $268 17 payments
  9. Kowa Pharmaceuticals America, Inc. $259 18 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $242 18 payments
  11. Other $1,682 108 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,381 370 payments
  2. Education $10 2 payments
Products named General payments · program years 2019–2025
  1. XARELTO $579 43 payments
  2. Prolia $396 29 payments
  3. EVENITY $370 27 payments
  4. TRULICITY $330 26 payments
  5. FARXIGA $319 13 payments
  6. JARDIANCE Diabetes $284 23 payments
  7. MYRBETRIQ $268 17 payments
  8. Livalo $259 18 payments
  9. JARDIANCE Diabetes $242 18 payments
  10. Ozempic $238 14 payments
  11. Other $4,709 322 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

372 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record